Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $11 from $12 and keeps a Buy rating on the shares post the Q1 report. The firm says its discussions with management further bolstered its conviction for CTx-1301 application filing, which it expects to occur in Q3. Roth’s base case assumes CTx-1301 FDA approval by Q4 of 2026 and launch by the first half of 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CING:
- Cingulate, Inc. Reports Increased Losses Amid R&D Expansion
- Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301
- Cingulate Inc Terminates Grant Agreement with Foundation
- Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301
- Cingulate announces results from high-dose fed/fast study of CTx-1301